Business
Uptick Newswire's Stock Day Podcast Interviews Nexien BioPharma CEO, Alex Wasyl, to Discuss the Acquisition of CRX Bio Holdings and The Company’s Future in The Pharmaceutical Space
Uptick Newswire's Stock Day Podcast Interviews Nexien BioPharma CEO, Alex Wasyl, to Discuss the Acquisition of CRX Bio Holdings and The Company’s Future in The Pharmaceutical Space.
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"DENVER, CO / ACCESSWIRE / November 26, 2018 / Nexien BioPharma, Inc. (OTCQB: NXEN) (''Nexien'' or the ''Company'') is a US-based pharmaceutical company focused on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. CEO, Alex Wasyl, joined Stock Day's Everett Jolly for the first time to discuss the recent acquisition of CRX Bio-Holdings by Nexien BioPharma, and the Company's future in the pharmaceutical industry.Jolly began the interview by asking Wasyl to provide some background information about the Company. Wasyl explained that Nexien BioPharma is the new name of a company that recently acquired CRX Bio-Holdings. He added, "We had a lot of synergies and synchronicities in management and intellectual property that led to the acquisition." He also explained thatNexien is a traditionally constructed pharmaceutical company in the United States, operating under full FDA compliance. Wasyl also noted that his background is in the life sciences sectors.Jolly inquired about the Company's progress on being listed on the CSE. Wasyl explained, "We are in the application process, and we have just filed a Restated and Amended Application, and we are very confident that we will be listed in due course and hopefully in the near future." And stated, "The listing on the CSE is not a funding event, but rather a stepping stone to a platform that we can use to continue our research and have greater capital access due to the more favorable investment environment in Canada."Wasyl mentioned that it was also important to note that they are not currently trading a lot ofvolume and recently the significant number of shares of stock for the Company went from restricted to free-float, so there is naturally some volatility in the stock. Wasyl continued, "Any near-term fundraising events will be mostly private placement."After noting the importance of an experienced management team, Jolly asked Wasyl to elaborate on the senior management staff of the Company. Wasyl responded, "There's a major synergy between former CRX Bio and now Nexien BioPharma as a collective. We were able to broaden the team's span of experience all the way from Wall Street down to bio-engineering and nano-materials." He continued by adding that the team has experts across several areas including ca...